Analysis of Quality of Life and Well-being from the Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Older Patients with Treatment-na ïve CLL (RESONATE-2TM)

CLL is a disease primarily of older patients for whom quality of life (QOL) is an important consideration. Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is indicated by the US FDA for the treatment of patients with CLL/small lymphocytic lymphoma and allows for treatment without chemotherapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Thomas Kipps, Paolo Ghia, Alessandra Tedeschi, Paul Barr, Tadeusz Robak, Carolyn Owen, Osnat Bairey, Peter Hillmen, Nancy Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Deverux, Helen McCarthy, Steven Coutre, Fritz Offner, Carol Moreno, Source Type: research